ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-19 09:13:00,2023-10-19T09:13:00-04:00,2023-10-19,"4 Ways to Grow $100,000 Into $1 Million for Retirement",Realty Income's total returns deliver. Alphabet is still turning investors into millionaires.,fool.com,https://www.fool.com/investing/2023/10/19/4-ways-to-grow-100000-into-1-million-for-retiremen/,https://images.financialmodelingprep.com/news/4-ways-to-grow-100000-into-1-million-for-20231019.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-19 09:30:00,2023-10-19T09:30:00-04:00,2023-10-19,1 Market-Beating Stock to Buy Near Its 52-Week High,Eli Lilly's obesity diabetes medicine Mounjaro continues to show excellent prospects. It should be the biggest growth driver behind the company's sales in the coming years.,fool.com,https://www.fool.com/investing/2023/10/19/1-market-beating-stock-to-buy-near-52-week-high/,https://images.financialmodelingprep.com/news/1-marketbeating-stock-to-buy-near-its-52week-high-20231019.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-19 13:58:42,2023-10-19T13:58:42-04:00,2023-10-19,Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source,"Eli Lilly has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-hires-cordenpharma-make-diabetes-drug-mounjaros-active-ingredient-source-2023-10-19/,https://images.financialmodelingprep.com/news/exclusive-lilly-hires-cordenpharma-to-make-diabetes-drug-mounjaros-20231019.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-19 16:11:36,2023-10-19T16:11:36-04:00,2023-10-19,7 Healthcare Stocks That Can Cure a Lackluster Portfolio,This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.,investorplace.com,https://investorplace.com/2023/10/healthcare-stocks-to-buy-4/,https://images.financialmodelingprep.com/news/7-healthcare-stocks-that-can-cure-a-lackluster-portfolio-20231019.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-19 16:58:33,2023-10-19T16:58:33-04:00,2023-10-19,Eli Lilly sues online pharmacies to ban US imports of fake Mounjaro,"Eli Lilly on Thursday said it sued 11 online pharmacies to stop them from importing, selling and distributing products claiming to contain the active ingredient in its diabetes drug Mounjaro, which is expected to be approved for weight loss later this year.",reuters.com,https://www.reuters.com/legal/eli-lilly-sues-online-pharmacies-ban-us-imports-fake-mounjaro-2023-10-19/,https://images.financialmodelingprep.com/news/eli-lilly-sues-online-pharmacies-to-ban-us-imports-20231019.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 06:24:00,2023-10-20T06:24:00-04:00,2023-10-20,Hundreds of online sellers are offering an Eli Lilly weight-loss drug that's years away from regulatory approval: WSJ,"Hundreds of online sellers are offering Eli Lilly' & Co.'s LLY, -2.71% retatrutide weight-loss drug for sale, even though the drug is years away from gaining regulatory approval, the Wall Street Journal reported Friday based on its own review of the matter. The bulk of the sellers appears to be Chinese who are shipping directly to U.S. consumers from sites such as one called Made-in-China.com.",marketwatch.com,https://www.marketwatch.com/story/hundreds-of-online-sellers-are-offering-an-eli-lilly-weight-loss-drug-thats-years-away-from-regulatory-approval-wsj-f4627bb3,https://images.financialmodelingprep.com/news/hundreds-of-online-sellers-are-offering-an-eli-lilly-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 06:35:02,2023-10-20T06:35:02-04:00,2023-10-20,Eli Lilly plans diabetes drug trial for kids as young as 6 years - Bloomberg,"Eli Lilly is planning a clinical trial of its diabetes drug Mounjaro in patients six years and older who have obesity, Bloomberg News reported on Friday, citing a person familiar with the matter.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-diabetes-drug-trial-kids-young-6-years-bloomberg-2023-10-20/,https://images.financialmodelingprep.com/news/eli-lilly-plans-diabetes-drug-trial-for-kids-as-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 06:45:00,2023-10-20T06:45:00-04:00,2023-10-20,Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years,"First readout of two-year data from long-term extension study INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company (NYSE: LLY). Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference happening from October 19-22 in Las Vegas, Nevada.1  ""Lebrikizumab, administered with a once-monthly dose following an induction phase, demonstrated efficacy for patients with moderate-to-severe atopic dermatitis, offering sustained relief from some of the most distressing signs and symptoms of the disease,"" said Emma Guttman-Yassky, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-lillys-lebrikizumab-monthly-maintenance-dosing-at-two-years-301962678.html,https://images.financialmodelingprep.com/news/nearly-80-of-patients-with-moderatetosevere-atopic-dermatitis-maintained-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 08:00:00,2023-10-20T08:00:00-04:00,2023-10-20,Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer,"Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% at 5 years These data reinforce two years of Verzenio plus endocrine therapy as the standard of care for these patients in this curative setting Use of Verzenio as a treatment option in this setting is supported by an NCCN® Category 1 designation INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced five-year outcomes from a pre-planned analysis of the Phase 3 monarchE study evaluating two years of adjuvant Verzenio® (abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. These data were shared in a late-breaking presentation at the 2023 European Society for Medical Oncology (ESMO) Congress.",prnewswire.com,https://www.prnewswire.com/news-releases/landmark-5-year-monarche-outcome-data-demonstrate-verzenio-abemaciclibs-long-term-impact-on-cancer-recurrence-in-high-risk-early-breast-cancer-301962737.html,https://images.financialmodelingprep.com/news/landmark-5year-monarche-outcome-data-demonstrate-verzenio-abemaciclibs-longterm-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 10:00:00,2023-10-20T10:00:00-04:00,2023-10-20,Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement,"INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-confirms-date-and-conference-call-for-third-quarter-2023-financial-results-announcement-301962605.html,https://images.financialmodelingprep.com/news/lilly-confirms-date-and-conference-call-for-thirdquarter-2023-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 11:40:10,2023-10-20T11:40:10-04:00,2023-10-20,DGRO: Can Dividends Generate Alpha?,DGRO: Can Dividends Generate Alpha?,seekingalpha.com,https://seekingalpha.com/article/4642160-dgro-can-dividends-generate-alpha,https://images.financialmodelingprep.com/news/dgro-can-dividends-generate-alpha-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-20 13:01:16,2023-10-20T13:01:16-04:00,2023-10-20,Eli Lilly planning diabetes drug trial for children six years and older: report,Eli Lilly and Co (NYSE:LLY) is planning a trial of its diabetes drug Mounjaro in patients with obesity as young as six years old according to a Bloomberg report Friday citing a person familiar with the matter. The company is already carrying out a Phase 3 trial of the drug in children as young as 10 years old and teenagers with type 2 diabetes.,proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1030513?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-planning-diabetes-drug-trial-for-children-six-20231020.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-21 10:31:00,2023-10-21T10:31:00-04:00,2023-10-21,Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and Presented in a Presidential Symposium at ESMO Congress 2023,"-  In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection ( RET) fusion-positive non-small cell lung cancer (NSCLC) - In the Phase 3 LIBRETTO-531 study, Retevmo provided a 72% improvement in PFS compared to cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) INDIANAPOLIS , Oct. 21, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from both the LIBRETTO-431 Phase 3 study, which evaluated Retevmo® (selpercatinib) versus platinum-based chemotherapy — with or without pembrolizumab — as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), and the LIBRETTO-531 Phase 3 study, which evaluated Retevmo versus multikinase inhibitors (MKIs) in patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). In both clinical studies, results were based on pre-specified interim efficacy analyses conducted by independent data monitoring committees (IDMC).",prnewswire.com,https://www.prnewswire.com/news-releases/lillys-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-cancer-and-ret-mutant-medullary-thyroid-cancer-both-published-in-the-new-england-journal-of-medicine-and-presented-in-a-presidential-sympo-301963757.html,https://images.financialmodelingprep.com/news/lillys-retevmo-selpercatinib-phase-3-results-in-ret-fusionpositive-20231021.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-23 08:19:00,2023-10-23T08:19:00-04:00,2023-10-23,Eli Lilly Is Waiting for Obesity-Drug Approval. Here's How Much It Could Be Worth.,Eli Lilly's diabetes drug Mounjaro is expected to be approved to treat obesity in the near future. It could drive sales for more than a decade.,barrons.com,https://www.barrons.com/articles/eli-lilly-stock-obesity-drug-mounjaro-ba60f38e,https://images.financialmodelingprep.com/news/eli-lilly-is-waiting-for-obesitydrug-approval-heres-how-20231023.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-23 15:47:24,2023-10-23T15:47:24-04:00,2023-10-23,Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers,"Citi notched its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. That view seems conservative.",cnbc.com,https://www.cnbc.com/2023/10/23/wall-street-hikes-forecasts-for-anti-obesity-drug-sales-to-100-billion.html,https://images.financialmodelingprep.com/news/wall-street-hikes-forecasts-for-antiobesity-drug-sales-to-20231023.jpeg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-24 06:30:00,2023-10-24T06:30:00-04:00,2023-10-24,Elektrofi and Lilly Enter Multi-Target Research Collaboration and License Agreement,Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation Combination of Elektrofi's ultra-high concentration microparticle suspension technology platform and Lilly's therapeutic expertise could expand new frontiers in patient-centric drug delivery innovation,globenewswire.com,https://www.globenewswire.com/news-release/2023/10/24/2765417/0/en/Elektrofi-and-Lilly-Enter-Multi-Target-Research-Collaboration-and-License-Agreement.html,https://images.financialmodelingprep.com/news/elektrofi-and-lilly-enter-multitarget-research-collaboration-and-license-20231024.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-24 10:32:47,2023-10-24T10:32:47-04:00,2023-10-24,Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It,"Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2170716/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-a-trending-stock-20231024.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-25 12:01:11,2023-10-25T12:01:11-04:00,2023-10-25,Inverse Jim Cramer Strategy - Q3 2023 Update,"Here is an update on our Inverse Jim Cramer strategy by taking a look at the results of his top stock picks for the quarter ending in September. This quarter, we collected and analyzed more than 400 of Cramer's stock picks. Cramer discussed stocks like Eli Lilly and Company, DraftKings, and Oracle the most in Q3.",seekingalpha.com,https://seekingalpha.com/article/4643323-inverse-jim-cramer-strategy-q3-2023-update,https://images.financialmodelingprep.com/news/inverse-jim-cramer-strategy-q3-2023-update-20231025.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-26 09:05:00,2023-10-26T09:05:00-04:00,2023-10-26,Will Eli Lilly Stock Be Worth More Than Tesla Stock by 2030?,"Eli Lilly has the potential to be a huge name in weight loss by the end of the decade. Tesla has significant potential in the electric vehicle market, but it could face a lot of competition.",fool.com,https://www.fool.com/investing/2023/10/26/will-eli-lilly-stock-be-worth-more-than-tesla-stoc/,https://images.financialmodelingprep.com/news/will-eli-lilly-stock-be-worth-more-than-tesla-20231026.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-26 10:00:00,2023-10-26T10:00:00-04:00,2023-10-26,Lilly to Participate in UBS Biopharma Conference 2023,"INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023. Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA; and chief customer officer, will participate in a fireside chat at 3 p.m.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-to-participate-in-ubs-biopharma-conference-2023-301967876.html,https://images.financialmodelingprep.com/news/lilly-to-participate-in-ubs-biopharma-conference-2023-20231026.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-26 11:19:18,2023-10-26T11:19:18-04:00,2023-10-26,Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline,Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2172796/earnings-preview-eli-lilly-lly-q3-earnings-expected-to-decline,https://images.financialmodelingprep.com/news/earnings-preview-eli-lilly-lly-q3-earnings-expected-to-20231026.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-26 18:24:00,2023-10-26T18:24:00-04:00,2023-10-26,"FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis","Omvoh achieved primary and key secondary endpoints, including sustained clinical remission in pivotal trials Omvoh delivered significant improvement in bowel urgency, reported by people with UC as one of the most disruptive symptoms Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Omvoh™ (mirikizumab-mrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults. Marking a significant milestone, Omvoh is the only UC treatment that selectively targets the p19 subunit of IL-23, which plays a role in inflammation related to UC.",prnewswire.com,https://www.prnewswire.com/news-releases/fda-approves-lillys-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis-301969505.html,https://images.financialmodelingprep.com/news/fda-approves-lillys-omvoh-mirikizumabmrkz-a-firstinclass-treatment-for-20231026.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-26 18:47:01,2023-10-26T18:47:01-04:00,2023-10-26,Eli Lilly's bowel disease drug gets US FDA's approval in adults,"Eli Lilly and Company said on Thursday that the U.S. health regulator had approved its drug for treating adults with moderately to severely active ulcerative colitis, a type of chronic inflammatory bowel disease.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lillys-bowel-disease-drug-gets-us-fdas-approval-adults-2023-10-26/,https://images.financialmodelingprep.com/news/eli-lillys-bowel-disease-drug-gets-us-fdas-approval-20231026.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-27 03:52:53,2023-10-27T03:52:53-04:00,2023-10-27,Eli Lilly bowel disease drug approved in US,"Eli Lilly and Co (NYSE:LLY) has announced that its Omvoh drug has been approved by the US Food and Drug Administration to treat types of inflammatory bowel disease. Following a third-phase 12-week clinical trial, in which Omvoh prompted responses in 65% of patients and remission in 24%, Eli Lilly announced the approval on Thursday.",proactiveinvestors.com,https://www.proactiveinvestors.co.uk/companies/news/1031188?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-bowel-disease-drug-approved-in-us-20231027.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-27 14:58:52,2023-10-27T14:58:52-04:00,2023-10-27,Eli Lilly diabetes drug Mounjaro will be in focus when the drugmaker reports earnings next week,"Eli Lilly and Co (NYSE:LLY) is scheduled to report earnings before the market opens on Thursday, with analysts expecting revenue growth but an earnings decline.  The drugmaker is expected to post a third-quarter adjusted loss of $0.15 per share on revenue of $8.95 billion, compared to earnings of $1.61 per share on revenue of $6.94 billion a year earlier.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1031280?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-diabetes-drug-mounjaro-will-be-in-focus-20231027.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-28 08:45:00,2023-10-28T08:45:00-04:00,2023-10-28,"Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?","Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.",fool.com,https://www.fool.com/investing/2023/10/28/roche-lilly-or-pfizer-whos-the-winner-in-ibd-wars/,https://images.financialmodelingprep.com/news/roche-lilly-or-pfizer-whos-the-winner-in-ibd-20231028.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-30 07:05:00,2023-10-30T07:05:00-04:00,2023-10-30,Albemarle Vs. Eli Lilly: 1 Potentially Set To Soar And 1 Bubble Stock To Ignore,"Valuation and fundamentals always matter, driving 97% of long-term stock returns. The market is capable of incredible ""fat pitch"" discounts and also creates insane bubbles. Albemarle Corporation is the world's leading lithium miner and is 65% undervalued, trading at less than 6X earnings, the lowest P/E in over 20 years.",seekingalpha.com,https://seekingalpha.com/article/4644385-albemarle-vs-eli-lilly-1-potentially-set-to-soar-and-1-bubble-stock-to-ignore,https://images.financialmodelingprep.com/news/albemarle-vs-eli-lilly-1-potentially-set-to-soar-and-20231030.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-30 12:03:02,2023-10-30T12:03:02-04:00,2023-10-30,"Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3",Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.,zacks.com,https://www.zacks.com/stock/news/2174606/busy-week-for-earnings-fed-reports-mcd-on-beat-in-q3,https://images.financialmodelingprep.com/news/busy-week-for-earnings-fed-reports-mcd-on-beat-20231030.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-31 08:37:02,2023-10-31T08:37:02-04:00,2023-10-31,Beam Therapeutics up 10% on $600m Lilly deal,Shares in Beam Therapeutics Inc were up 10% premarket following a deal to sell rights to a licensing deal with Verve Therapeutics to Eli Lilly and Co (NYSE:LLY). An upfront $250 million cash and paper payment could balloon to $600 million based on milestones.,proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1031525?SNAPI,https://images.financialmodelingprep.com/news/beam-therapeutics-up-10-on-600m-lilly-deal-20231031.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-31 10:12:33,2023-10-31T10:12:33-04:00,2023-10-31,Eli Lilly Stock Has Quadrupled in 3 Years. Could a Weight-Loss Drug Approval Make It Happen Again?,Speculation and hype created the bulk of Eli Lilly's bullishness of late rather than plausible fundamentals. The rampant speculation around Mounjaro leaves Lilly stock highly vulnerable to bearish volatility.,fool.com,https://www.fool.com/investing/2023/10/31/eli-lilly-stock-quadrupled-weight-loss-drug/,https://images.financialmodelingprep.com/news/eli-lilly-stock-has-quadrupled-in-3-years-could-20231031.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-31 13:54:52,2023-10-31T13:54:52-04:00,2023-10-31,Verve Stock Soars On $250 Million Eli Lilly Deal,Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.,investors.com,https://www.investors.com/news/technology/verv-stock-skyrockets-after-lilly-inks-deal-for-its-gene-editing-drugs/,https://images.financialmodelingprep.com/news/verve-stock-soars-on-250-million-eli-lilly-deal-20231031.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-31 16:48:26,2023-10-31T16:48:26-04:00,2023-10-31,AI-Powered Investing: 3 Promising Stocks for 2024,Stock predictions by AI (artificial intelligence) are becoming more popular with investors.  More actively managed ETFs are launching driven by AI.,investorplace.com,https://investorplace.com/2023/10/ai-powered-investing-3-promising-stocks-for-2024/,https://images.financialmodelingprep.com/news/aipowered-investing-3-promising-stocks-for-2024-20231031.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-10-31 19:09:02,2023-10-31T19:09:02-04:00,2023-10-31,Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today,The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.,fool.com,https://www.fool.com/investing/2023/10/31/why-beam-and-verve-therapeutics-stock-soared-while/,https://images.financialmodelingprep.com/news/why-beam-and-verve-therapeutics-shares-soared-while-eli-20231031.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-01 06:07:07,2023-11-01T06:07:07-04:00,2023-11-01,Investor patience tested as pharmaceutical stocks take a tumble,The Health Care Select Sector SPDR Fund NYSEARCA: XLV was down 3.81% in the past month and 8.03% in the past three months. The latest round of pharmaceutical stock earnings isn't helping sector performance.,marketbeat.com,https://www.marketbeat.com/originals/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble/?utm_source=snapi,https://images.financialmodelingprep.com/news/investor-patience-tested-as-pharmaceutical-stocks-take-a-tumble-20231101.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-01 06:55:00,2023-11-01T06:55:00-04:00,2023-11-01,Lilly Declares Fourth-Quarter 2023 Dividend,"INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Dec. 8, 2023 to shareholders of record at the close of business on Nov. 15, 2023.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-declares-fourth-quarter-2023-dividend-301973013.html,https://images.financialmodelingprep.com/news/lilly-declares-fourthquarter-2023-dividend-20231101.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-01 08:00:00,2023-11-01T08:00:00-04:00,2023-11-01,"Hip-Hop Classic ""It Takes Two"" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease","Boehringer Ingelheim and Lilly team up with hip-hop artist Rob Base for the launch of It Takes 2™ – a new health initiative  to educate healthcare professionals and adults at risk for kidney disease on the condition's unknown nature  and the benefits of complete testing Clinical guidelines recommend both blood and urine tests for complete screening for kidney disease: estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) tests RIDGEFIELD, Conn. and INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- More than 35 million adults in the U.S. have chronic kidney disease (CKD).",prnewswire.com,https://www.prnewswire.com/news-releases/hip-hop-classic-it-takes-two-takes-on-new-meaning-in-remix-to-elevate-importance-of-testing-for-kidney-disease-301973489.html,https://images.financialmodelingprep.com/news/hiphop-classic-it-takes-two-takes-on-new-meaning-20231101.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-01 10:34:21,2023-11-01T10:34:21-04:00,2023-11-01,Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics,"Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",zacks.com,https://www.zacks.com/stock/news/2176355/curious-about-lilly-lly-q3-performance-explore-wall-street-estimates-for-key-metrics,https://images.financialmodelingprep.com/news/curious-about-lilly-lly-q3-performance-explore-wall-street-20231101.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 04:34:00,2023-11-02T04:34:00-04:00,2023-11-02,"Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies",Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.,marketwatch.com,https://www.marketwatch.com/story/weight-loss-drug-maker-reports-56-profit-surge-as-it-continues-to-limit-supplies-183b19b8,https://images.financialmodelingprep.com/news/weightloss-drug-maker-reports-56-profit-surge-as-it-continues-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:30:00,2023-11-02T06:30:00-04:00,2023-11-02,"Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity","Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-reports-third-quarter-2023-financial-results-highlights-strong-sales-growth-and-business-development-activity-301975008.html,https://images.financialmodelingprep.com/news/lilly-reports-thirdquarter-2023-financial-results-highlights-strong-sales-growth-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:36:35,2023-11-02T06:36:35-04:00,2023-11-02,Eli Lilly beats quarterly revenue estimates on Mounjaro strength,"Eli Lilly beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-beats-quarterly-revenue-estimates-mounjaro-strength-2023-11-02/,https://images.financialmodelingprep.com/news/eli-lilly-beats-quarterly-revenue-estimates-on-mounjaro-strength-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:40:00,2023-11-02T06:40:00-04:00,2023-11-02,7 A-Rated Tech Stocks to Buy for November,Last year wasn't the best year for tech stocks. Some of the biggest names on Wall Street stumbled through the year as companies that were flush with growth during the Covid-19 pandemic adjusted to leaner times.,investorplace.com,https://investorplace.com/2023/11/7-a-rated-tech-stocks-to-buy-for-november/,https://images.financialmodelingprep.com/news/7-arated-tech-stocks-to-buy-for-november-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:51:00,2023-11-02T06:51:00-04:00,2023-11-02,Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed,"Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but slashed its full-year outlook, due primarily to acquired in-process research and development charges. The company swung to a net loss of $57.4 million, or 6 cents a share, from net income of $1.45 billion, or $1.61 a share, in the year-ago period.",marketwatch.com,https://www.marketwatch.com/story/eli-lillys-stock-drops-after-surprise-profit-is-reported-but-full-year-outlook-was-slashed-a2a42621,https://images.financialmodelingprep.com/news/eli-lillys-stock-drops-after-surprise-profit-is-reported-but-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:54:00,2023-11-02T06:54:00-04:00,2023-11-02,Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically,"Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.",barrons.com,https://www.barrons.com/articles/eli-lilly-stock-earnings-4d10019a,https://images.financialmodelingprep.com/news/eli-lilly-stock-falls-as-earnings-guidance-slashed-dramatically-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 06:56:18,2023-11-02T06:56:18-04:00,2023-11-02,Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook,"Eli Lilly reported revenue and adjusted earnings that topped expectations, lifted by $1.4 billion in sales from its blockbuster diabetes drug Mounjaro.",cnbc.com,https://www.cnbc.com/2023/11/02/eli-lilly-lly-q3-earnings-report-2023.html,https://images.financialmodelingprep.com/news/eli-lilly-results-top-estimates-on-mounjaro-strength-but-20231102.jpeg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 09:00:00,2023-11-02T09:00:00-04:00,2023-11-02,Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting,"INDIANAPOLIS , Nov. 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12 in San Diego. The presentations will provide updated, longer follow-up clinical safety and efficacy data for approved and investigational uses of pirtobrutinib from the ongoing Phase 1/2 BRUIN study in multiple B-cell malignancies.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash-annual-meeting-301974498.html,https://images.financialmodelingprep.com/news/lilly-announces-details-of-pirtobrutinib-presentations-in-bcell-malignancies-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 10:56:14,2023-11-02T10:56:14-04:00,2023-11-02,Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook,"Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, marking a 44% increase from the previous quarter and surpassing analysts' estimates of $1.26 billion.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1031876?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-sees-strong-3q-sales-fueled-by-mounjaro-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 10:59:32,2023-11-02T10:59:32-04:00,2023-11-02,Why Eli Lilly Stock Is Jumping Today,"Lilly's Q3 revenue soared, but its earnings sank. However, the company's top- and bottom-line results handily beat Wall Street estimates.",fool.com,https://www.fool.com/investing/2023/11/02/why-eli-lilly-stock-is-jumping-today/,https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-jumping-today-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 12:00:56,2023-11-02T12:00:56-04:00,2023-11-02,Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.,The remarks suggest that Eli Lilly's initial efforts to expand manufacturing capacity for Mounjaro are paying off as demand for the diabetes treatment soars.,cnbc.com,https://www.cnbc.com/2023/11/02/eli-lilly-diabetes-drug-mounjaro-supply-improves-in-us.html,https://images.financialmodelingprep.com/news/eli-lilly-says-supply-of-blockbuster-diabetes-drug-mounjaro-20231102.jpeg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 12:02:25,2023-11-02T12:02:25-04:00,2023-11-02,"Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up",Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.,zacks.com,https://www.zacks.com/stock/news/2177427/eli-lilly-lly-q3-earnings-sales-top-eps-view-cut-stock-up,https://images.financialmodelingprep.com/news/eli-lilly-lly-q3-earnings-sales-top-eps-view-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 12:02:47,2023-11-02T12:02:47-04:00,2023-11-02,"Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics","While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2177394/compared-to-estimates-lilly-lly-q3-earnings-a-look-at-key-metrics,https://images.financialmodelingprep.com/news/compared-to-estimates-lilly-lly-q3-earnings-a-look-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 13:16:08,2023-11-02T13:16:08-04:00,2023-11-02,"Novo Nordisk, Lilly see insatiable demand for weight-loss drugs",Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-lilly-see-insatiable-demand-weight-loss-drugs-2023-11-02/,https://images.financialmodelingprep.com/news/novo-nordisk-lilly-see-insatiable-demand-for-weightloss-drugs-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-02 14:07:09,2023-11-02T14:07:09-04:00,2023-11-02,Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript,Eli Lilly and Co (LLY) Q3 2023 Earnings Conference Call Transcript,seekingalpha.com,https://seekingalpha.com/article/4646632-eli-lilly-and-co-lly-q3-2023-earnings-conference-call-transcript,https://images.financialmodelingprep.com/news/eli-lilly-and-co-lly-q3-2023-earnings-conference-20231102.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-03 09:45:00,2023-11-03T09:45:00-04:00,2023-11-03,Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?,Eli Lilly just earned FDA approval of a treatment for ulcerative colitis. There is already plenty of competition on the market for this condition.,fool.com,https://www.fool.com/investing/2023/11/03/eli-lilly-just-added-another-potential-billion/,https://images.financialmodelingprep.com/news/eli-lilly-just-added-another-potential-billiondollar-product-is-20231103.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-03 12:47:47,2023-11-03T12:47:47-04:00,2023-11-03,Eli Lilly Beats on Q3 Earnings: ETFs to Buy,"Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.",zacks.com,https://www.zacks.com/stock/news/2178224/eli-lilly-beats-on-q3-earnings-etfs-to-buy,https://images.financialmodelingprep.com/news/eli-lilly-beats-on-q3-earnings-etfs-to-buy-20231103.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-03 12:56:15,2023-11-03T12:56:15-04:00,2023-11-03,The Importance of Brand Power: 3 Stocks to Consider,Brand power is real. The brand that consumers associate with a company is quantifiable and something valued.,investorplace.com,https://investorplace.com/2023/11/the-importance-of-brand-power-3-stocks-to-consider/,https://images.financialmodelingprep.com/news/the-importance-of-brand-power-3-stocks-to-consider-20231103.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-06 15:32:00,2023-11-06T15:32:00-05:00,2023-11-06,"The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli",Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades–the kind of drugs that should be cheap.,marketwatch.com,https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a,https://images.financialmodelingprep.com/news/the-doctor-lowering-drug-prices-for-1-million-patients-20231106.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-06 15:44:53,2023-11-06T15:44:53-05:00,2023-11-06,IHE: You Better Like Eli Lilly And Johnson & Johnson To Buy This,"The iShares U.S. Pharmaceuticals ETF provides targeted exposure to the U.S. pharmaceutical industry but has a highly concentrated portfolio. The IHE ETF's top five holdings, including Eli Lilly and Johnson & Johnson, account for over 63% of the fund's total assets, posing a concentration risk. Compared to its peers, IHE has a lower expense ratio but higher concentration of holdings, which may increase risk for investors.",seekingalpha.com,https://seekingalpha.com/article/4648112-ihe-you-better-like-eli-lilly-and-johnson-and-johnson-to-buy-this,https://images.financialmodelingprep.com/news/ihe-you-better-like-eli-lilly-and-johnson-johnson-20231106.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-06 16:21:13,2023-11-06T16:21:13-05:00,2023-11-06,"Eli Lilly, Power Generators Lead Top S&P 500 Performers Monday","Eli Lilly was an S&P 500 top performer Monday, while energy plays were among the day's biggest winners and losers.",investors.com,https://www.investors.com/news/sp-500-eli-lilly-among-top-performers-monday/,https://images.financialmodelingprep.com/news/eli-lilly-power-generators-lead-top-sp-500-performers-20231106.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-07 10:32:11,2023-11-07T10:32:11-05:00,2023-11-07,Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know,"Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2179968/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-is-attracting-investor-attention-20231107.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 07:18:00,2023-11-08T07:18:00-05:00,2023-11-08,Grab these 2 funds with rich 11%-12% yields while you can,With much of the U.S. stock market in a correction there are plenty of attractive stocks to consider. This is especially true in income investing.,marketwatch.com,https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2,https://images.financialmodelingprep.com/news/grab-these-2-funds-with-rich-1112-yields-while-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 08:20:00,2023-11-08T08:20:00-05:00,2023-11-08,Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?,"Eli Lilly now forecasts that it will have lower profits this year than previously projected. Usually, announcements of that type take the wind out of a stock's price.",fool.com,https://www.fool.com/investing/2023/11/08/eli-lilly-slashed-its-earnings-guidance-and-its-st/,https://images.financialmodelingprep.com/news/eli-lilly-slashed-its-earnings-guidance-and-its-stock-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 12:20:36,2023-11-08T12:20:36-05:00,2023-11-08,"FDA approves Eli Lilly's tirzepatide for obesity, paving way for even wider use of blockbuster drug",The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug industry.,cnbc.com,https://www.cnbc.com/2023/11/08/fda-approves-eli-lilly-drug-tirzepatide-for-obesity.html,https://images.financialmodelingprep.com/news/fda-approves-eli-lillys-tirzepatide-for-obesity-paving-way-20231108.jpeg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 12:35:59,2023-11-08T12:35:59-05:00,2023-11-08,U.S. FDA approves Lilly's weight-loss drug,"The U.S. Food and Drug Administration on Wednesday approved Eli Lilly's drug for weight loss, according to data on the agency's website, giving the drugmaker entry into a lucrative market that has captured Wall Street's enthusiasm this year.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-lillys-weight-loss-drug-2023-11-08/,https://images.financialmodelingprep.com/news/us-fda-approves-lillys-weightloss-drug-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 12:45:00,2023-11-08T12:45:00-05:00,2023-11-08,Eli Lilly's Obesity Drug Gets FDA Approval,The drug will be marketed as an obesity treatment under the name Zepbound.,barrons.com,https://www.barrons.com/articles/eli-lilly-obesity-drug-1aded298,https://images.financialmodelingprep.com/news/eli-lillys-obesity-drug-gets-fda-approval-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 13:22:00,2023-11-08T13:22:00-05:00,2023-11-08,Eli Lilly gets FDA approval for new obesity drug,"The U.S. Food and Drug Administration on Wednesday approved Eli Lilly & Co.'s LLY, +1.74% obesity drug Zepbound, which in clinical trials helped patients lose up to 48 pounds on average.",marketwatch.com,https://www.marketwatch.com/story/eli-lilly-gets-fda-approval-for-new-obesity-drug-ef514794,https://images.financialmodelingprep.com/news/eli-lilly-gets-fda-approval-for-new-obesity-drug-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 13:34:49,2023-11-08T13:34:49-05:00,2023-11-08,Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug,The FDA approved a highly anticipated weight-loss drug from Eli Lilly on Wednesday. Eli Lilly stock rose less than 2% after the release.,investors.com,https://www.investors.com/news/technology/eli-lilly-stock-lilly-wins-fda-approval-for-highly-anticipated-weight-loss-drug/,https://images.financialmodelingprep.com/news/eli-lilly-wins-fda-approval-for-highly-anticipated-weightloss-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 14:14:42,2023-11-08T14:14:42-05:00,2023-11-08,LLY stock jumps after FDA approves Eli Lilly's tirzepatide drug for weight loss,"Eli Lilly And Co's (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration's (FDA) approval of their blockbuster drug tirzepatide for weight loss.",invezz.com,https://invezz.com/news/2023/11/08/lly-stock-jumps-after-fda-approves-eli-lillys-tirzepatide-drug-for-weight-loss/?utm_source=snapi,https://images.financialmodelingprep.com/news/lly-stock-jumps-after-fda-approves-eli-lillys-tirzepatide-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 15:04:18,2023-11-08T15:04:18-05:00,2023-11-08,What to know about Eli Lilly's new obesity drug,"The U.S. Food and Drug Administration approved Eli Lilly's keenly-awaited obesity treatment on Wednesday, introducing a powerful rival to Novo Nordisk's popular weight-loss therapy Wegovy.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/what-know-about-eli-lillys-new-obesity-drug-2023-11-08/,https://images.financialmodelingprep.com/news/what-to-know-about-eli-lillys-new-obesity-drug-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 15:22:57,2023-11-08T15:22:57-05:00,2023-11-08,UK's MHRA authorises Eli Lilly's Mounjaro,Britain's health regulator on Wednesday authorised Eli Lilly's diabetes drug Mounjaro for weight management and weight loss in the UK.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/uks-mhra-authorises-eli-lillys-mounjaro-2023-11-08/,https://images.financialmodelingprep.com/news/uks-mhra-authorises-eli-lillys-mounjaro-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 15:38:33,2023-11-08T15:38:33-05:00,2023-11-08,FDA Approves Diabetes Drug Mounjaro For Weight Loss Under Brand Name Zepbound,Eli Lilly's Zepbound helped users lose up to 22.5% of their weight in clinical trials.,forbes.com,https://www.forbes.com/sites/britneynguyen/2023/11/08/fda-approves-diabetes-drug-mounjaro-for-weight-loss-under-brand-name-zepbound/,https://images.financialmodelingprep.com/news/fda-approves-diabetes-drug-mounjaro-for-weight-loss-under-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 16:56:00,2023-11-08T16:56:00-05:00,2023-11-08,Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma,"INDIANAPOLIS , Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares (""Shares"") of common stock of POINT Biopharma Global Inc. (NASDAQ: PNT), for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-301982413.html,https://images.financialmodelingprep.com/news/lilly-announces-extension-of-tender-offer-to-acquire-point-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 18:10:38,2023-11-08T18:10:38-05:00,2023-11-08,Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment,"Eli Lilly (LLY) shares hit an all-time high Wednesday after the Food and Drug Administration (FDA) approved the drug maker's Zepbound injection to treat people who are obese or are overweight and also have weight-related medical problems, such as hypertension and Type 2 diabetes.",investopedia.com,https://www.investopedia.com/eli-lilly-shares-hit-all-time-high-after-fda-approves-drug-for-weight-loss-treatment-8399595,https://images.financialmodelingprep.com/news/eli-lilly-shares-hit-alltime-high-after-fda-approves-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 19:32:10,2023-11-08T19:32:10-05:00,2023-11-08,Earnings Estimates Come Under Pressure,"While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.",zacks.com,https://www.zacks.com/commentary/2181217/earnings-estimates-come-under-pressure,https://images.financialmodelingprep.com/news/earnings-estimates-come-under-pressure-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-08 19:32:11,2023-11-08T19:32:11-05:00,2023-11-08,Earnings Estimates Come Under Pressure,"While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.",zacks.com,https://www.zacks.com/commentary/2181196/earnings-estimates-come-under-pressure,https://images.financialmodelingprep.com/news/earnings-estimates-come-under-pressure-20231108.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 07:48:59,2023-11-09T07:48:59-05:00,2023-11-09,'Wonder' diabetes drug Mounjaro approved in the UK,"Diabetes blockbuster Mounjaro has been approved for use by the UK drugs agency MHRA after two clinical trials showed patients taking shed between 16%-22% of their weight in little more than a year. Designed to help people with diabetes, demand for US giant Eli LIlly's drug has rocketed as people have turned to it as a panacea to lose weight.",proactiveinvestors.com,https://www.proactiveinvestors.co.uk/companies/news/1032620?SNAPI,https://images.financialmodelingprep.com/news/wonder-diabetes-drug-mounjaro-approved-in-the-uk-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 08:00:00,2023-11-09T08:00:00-05:00,2023-11-09,1 Cathie Wood Stock to Buy Hand Over Fist Right Now,"Cathie Wood's ARK Invest family of ETFs focuses on the interrelated concepts of innovation and disruption. Verve Therapeutics, a holding in two of her better-known ETFs, appears primed for a sustained move higher.",fool.com,https://www.fool.com/investing/2023/11/09/1-cathie-wood-stock-to-buy-hand-over-fist-right-no/,https://images.financialmodelingprep.com/news/1-cathie-wood-stock-to-buy-hand-over-fist-right-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 08:38:27,2023-11-09T08:38:27-05:00,2023-11-09,Eli Lilly: still seeking UK approval on pen for weight-loss drug,"Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of the product's launch.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-still-seeking-uk-approval-pen-weight-loss-drug-2023-11-09/,https://images.financialmodelingprep.com/news/eli-lilly-still-seeking-uk-approval-on-pen-for-weightloss-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 10:23:00,2023-11-09T10:23:00-05:00,2023-11-09,3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates,"Eli Lilly's strong prospects have given investors plenty of reason to remain bullish despite rising interest rates. Axsome has gone from reporting no sales to now having a couple of strong, revenue-generating assets.",fool.com,https://www.fool.com/investing/2023/11/09/3-healthcare-stocks-that-have-more-than-doubled/,https://images.financialmodelingprep.com/news/3-healthcare-stocks-that-have-more-than-doubled-in-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 11:08:16,2023-11-09T11:08:16-05:00,2023-11-09,Why Eli Lilly Stock Is Slumping Today,"The FDA approved Lilly's Zepbound (tirzepatide) for chronic weight loss management. Today's decline appears to be a case of investors ""buying the rumor and selling the news.",fool.com,https://www.fool.com/investing/2023/11/09/why-eli-lilly-stock-is-slumping-today/,https://images.financialmodelingprep.com/news/why-eli-lilly-stock-is-slumping-today-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 13:43:19,2023-11-09T13:43:19-05:00,2023-11-09,Eli Lilly's Big Win In The Obesity Space Just Got Bigger,"Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase in shareholder wealth. Tirzepatide has shown promising results in clinical trials, with patients losing an average of 48 pounds over 72 weeks.",seekingalpha.com,https://seekingalpha.com/article/4649863-eli-lilly-big-win-in-the-obesity-space-just-got-bigger,https://images.financialmodelingprep.com/news/eli-lillys-big-win-in-the-obesity-space-just-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-09 14:09:00,2023-11-09T14:09:00-05:00,2023-11-09,Lilly Takes First Jab in Obesity Drug Showdown,Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.,barrons.com,https://www.barrons.com/articles/eli-lilly-novo-nordisk-stock-weight-loss-drug-d86bac08,https://images.financialmodelingprep.com/news/lilly-takes-first-jab-in-obesity-drug-showdown-20231109.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 05:40:00,2023-11-10T05:40:00-05:00,2023-11-10,Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.,"Eli Lilly set some ambitious goals for 2023, highlighting a promising mix of assets in its portfolio. The company has obtained multiple drug approvals this year.",fool.com,https://www.fool.com/investing/2023/11/10/eli-lilly-was-hoping-for-5-big-drug-launches-this/,https://images.financialmodelingprep.com/news/eli-lilly-was-hoping-for-5-big-drug-launches-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 06:03:10,2023-11-10T06:03:10-05:00,2023-11-10,British regulator confirms review of new pen for Lilly's Mounjaro drug,"Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugmaker's Mounjaro drug against obesity and diabetes.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/british-regulator-confirms-review-new-pen-lillys-mounjaro-drug-2023-11-10/,https://images.financialmodelingprep.com/news/british-regulator-confirms-review-of-new-pen-for-lillys-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 06:30:08,2023-11-10T06:30:08-05:00,2023-11-10,Will Eli Lilly's Zepbound be the next big weight-loss drug?,Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.,marketbeat.com,https://www.marketbeat.com/originals/will-eli-lillys-zepbound-be-the-next-big-weight-loss-drug/?utm_source=snapi,https://images.financialmodelingprep.com/news/will-eli-lillys-zepbound-be-the-next-big-weightloss-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 06:50:00,2023-11-10T06:50:00-05:00,2023-11-10,The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?,There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.,fool.com,https://www.fool.com/investing/2023/11/10/the-alzheimers-drug-market-is-heating-up-should-yo/,https://images.financialmodelingprep.com/news/the-alzheimers-drug-market-is-heating-up-should-you-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 07:31:27,2023-11-10T07:31:27-05:00,2023-11-10,EU regulator backs Eli Lilly's Mounjaro for weight management,Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-eli-lillys-mounjaro-weight-management-2023-11-10/,https://images.financialmodelingprep.com/news/eu-regulator-backs-eli-lillys-mounjaro-for-weight-management-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 10:23:00,2023-11-10T10:23:00-05:00,2023-11-10,Where Will Eli Lilly Be in 5 Years?,"Eli Lilly is pulling out all the stops to gain market share in a pair of key markets. It'll face stiff opposition from Novo Nordisk, among other contenders.",fool.com,https://www.fool.com/investing/2023/11/10/where-will-eli-lilly-be-in-5-years/,https://images.financialmodelingprep.com/news/where-will-eli-lilly-be-in-5-years-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 12:20:06,2023-11-10T12:20:06-05:00,2023-11-10,3 Stocks to Buy for Retirees Looking to Beat Inflation,"At 3.7%, inflation remains an issue. While consumer prices have come down from their peak of 9.1% in June 2022, the inflation rate in the U.S. remains well above the Federal Reserve's 2% annualized target.",investorplace.com,https://investorplace.com/2023/11/3-stocks-to-buy-for-retirees-looking-to-beat-inflation/,https://images.financialmodelingprep.com/news/3-stocks-to-buy-for-retirees-looking-to-beat-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 12:21:00,2023-11-10T12:21:00-05:00,2023-11-10,Here's how Eli Lilly might bring a game-changing Alzheimer's drug to market,"As part of the MarketWatch 50 series, Eleanor Laise interviewed Dr. Daniel Skovronsky, the chief scientific and medical officer at Eli Lilly & Co. LLY, +0.11%. The company's stock has soared 63% this year amid excitement for its Mounjaro treatment for Type 2 diabetes.",marketwatch.com,https://www.marketwatch.com/story/heres-how-eli-lilly-might-bring-a-game-changing-alzheimers-drug-to-market-6895dbc5,https://images.financialmodelingprep.com/news/heres-how-eli-lilly-might-bring-a-gamechanging-alzheimers-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-10 13:05:07,2023-11-10T13:05:07-05:00,2023-11-10,Eli Lilly's Tirzepatide approved in the EU days after US and UK approval,"Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the United Kingdom. The stock, took a dive on Thursday to close at $591.49 after enjoying a surge on Wednesday especially following the approval by the US FDA.",invezz.com,https://invezz.com/news/2023/11/10/days-after-us-and-uk-approval-eli-lillys-tirzepatide-approved-in-the-eu/?utm_source=snapi,https://images.financialmodelingprep.com/news/eli-lillys-tirzepatide-approved-in-the-eu-days-after-20231110.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-11 05:00:00,2023-11-11T05:00:00-05:00,2023-11-11,Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth,Eli Lilly just gained approval for a drug that could win big in the multibillion-dollar weight-loss market. Johnson & Johnson is focusing on its high-growth businesses after the recent spinoff of its consumer health unit.,fool.com,https://www.fool.com/investing/2023/11/11/cautious-investor-2-safe-stocks-you-also-can-count/,https://images.financialmodelingprep.com/news/cautious-investor-2-safe-stocks-you-also-can-count-20231111.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-11 13:01:04,2023-11-11T13:01:04-05:00,2023-11-11,Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript),"Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huynh - UBS Trung Huynh Okay. We're at the hour now.",seekingalpha.com,https://seekingalpha.com/article/4650806-eli-lilly-and-company-lly-presents-ubs-biopharma-2023-conference-transcript,https://images.financialmodelingprep.com/news/eli-lilly-and-company-lly-presents-at-ubs-biopharma-20231111.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 03:22:32,2023-11-13T03:22:32-05:00,2023-11-13,Eli Lilly: Favorable Developments Continue Regarding Anti-Obesity Drug Franchise,"Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse cardiovascular events and has additional benefits such as weight loss. The anti-obesity drug class is projected to generate $150 billion in US revenues by 2030, with injectables being the primary choice for the next 18 months. Oral medications are expected to be approved in 2025-2026.",seekingalpha.com,https://seekingalpha.com/article/4651116-eli-lilly-favorable-developments-continue-regarding-anti-obesity-drug-franchise,https://images.financialmodelingprep.com/news/eli-lilly-favorable-developments-continue-regarding-antiobesity-drug-franchise-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 06:17:00,2023-11-13T06:17:00-05:00,2023-11-13,Better Buy Now: Novo Nordisk vs. Eli Lilly,Novo Nordisk's weight management blockbuster produced some surprising results for its ability to reduce patients' risk of a second heart attack. The Food and Drug Administration recently approved Eli Lilly's weight management drug Zepbound.,fool.com,https://www.fool.com/investing/2023/11/13/better-buy-now-novo-nordisk-vs-eli-lilly/,https://images.financialmodelingprep.com/news/better-buy-now-novo-nordisk-vs-eli-lilly-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 08:56:07,2023-11-13T08:56:07-05:00,2023-11-13,The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight',The magnificent seven stocks have captured a lot of investor attention and investment in 2023. Those seven tech firms have been responsible for a great portion of the overall market rebound this year.,investorplace.com,https://investorplace.com/2023/11/the-magnificent-seven-7-stocks-that-could-make-it-the-elite-eight/,https://images.financialmodelingprep.com/news/the-magnificent-seven-7-stocks-that-could-make-it-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 11:17:10,2023-11-13T11:17:10-05:00,2023-11-13,4 Large Drug Stocks Likely to Sail Through Industry Woes,"Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.",zacks.com,https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes,https://images.financialmodelingprep.com/news/4-large-drug-stocks-likely-to-sail-through-industry-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 11:42:55,2023-11-13T11:42:55-05:00,2023-11-13,Eli Lilly's experimental heart drug cuts genetic risk factor by 94% for a year,"Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human trial has shown. Lipoprotein (a) is a form of cholesterol that is a genetic risk factor for a range of conditions including coronary artery disease, stroke, and thrombosis.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1032929?SNAPI,https://images.financialmodelingprep.com/news/eli-lillys-experimental-heart-drug-cuts-genetic-risk-factor-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 13:42:01,2023-11-13T13:42:01-05:00,2023-11-13,Eli Lilly's experimental drug lowers risk of heart disease by 94%: study,"Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.",nypost.com,https://nypost.com/2023/11/13/business/eli-lillys-experimental-drug-lowers-risk-of-heart-disease-by-94-study/,https://images.financialmodelingprep.com/news/eli-lillys-experimental-drug-lowers-risk-of-heart-disease-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-13 13:42:54,2023-11-13T13:42:54-05:00,2023-11-13,Eli Lilly rides on Novo's coattails as BofA analysts maintain ‘Buy' rating following SELECT trial data,"Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities said they were more favorable than expected. In a note to clients, the analysts said Nova's cardiovascular (CV) trial provides another “feather in weight-loss drugs cap,” creating a favorable set-up for Eli Lilly and Co (NYSE:LLY) and its CV outcomes trial, SURMOUNT-MMO.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1032940?SNAPI,https://images.financialmodelingprep.com/news/eli-lilly-rides-on-novos-coattails-as-bofa-analysts-20231113.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-14 07:45:00,2023-11-14T07:45:00-05:00,2023-11-14,Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning,Eli Lilly's weight-loss medicine Zepbound was just approved for sale by regulators. It's buying businesses and making investments to drive further growth.,fool.com,https://www.fool.com/investing/2023/11/14/eli-lilly-is-planning-to-dominate-the-weight-loss/,https://images.financialmodelingprep.com/news/eli-lilly-is-planning-to-dominate-the-weight-loss-20231114.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-14 10:00:00,2023-11-14T10:00:00-05:00,2023-11-14,Lilly to Participate in Evercore ISI HealthCONx Conference,"INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023. Daniel Skovronsky, M.D.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-to-participate-in-evercore-isi-healthconx-conference-301986604.html,https://images.financialmodelingprep.com/news/lilly-to-participate-in-evercore-isi-healthconx-conference-20231114.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-14 16:06:08,2023-11-14T16:06:08-05:00,2023-11-14,Why It's Time to Sell These 3 Hot Stocks,"Stock gains are great, but they don't necessarily continue forever. Today's fast rising investment can be tomorrow's disappointment.",investorplace.com,https://investorplace.com/2023/11/why-its-time-to-sell-these-3-hot-stocks/,https://images.financialmodelingprep.com/news/why-its-time-to-sell-these-3-hot-stocks-20231114.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-14 16:33:00,2023-11-14T16:33:00-05:00,2023-11-14,Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma,"INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Nuclear Regulatory Commission (""NRC"") has issued its consent for the indirect transfer of control of POINT Biopharma Global Inc.'s (NASDAQ: PNT) radioactive materials license (the ""NRC Consent""), which will occur following the completion of Lilly's previously announced tender offer to acquire all of the issued and outstanding shares (""Shares"") of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction.",prnewswire.com,https://www.prnewswire.com/news-releases/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma-301988209.html,https://images.financialmodelingprep.com/news/lilly-announces-the-receipt-of-nrc-consent-in-connection-20231114.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-14 18:46:01,2023-11-14T18:46:01-05:00,2023-11-14,Investors increase holdings of weight-loss drug makers' shares in Q3 -filings,"Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filings showed on Tuesday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/investors-increase-holdings-weight-loss-drug-makers-shares-q3-filings-2023-11-14/,https://images.financialmodelingprep.com/news/investors-increase-holdings-of-weightloss-drug-makers-shares-in-20231114.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-15 14:04:47,2023-11-15T14:04:47-05:00,2023-11-15,Lilly plans single-digit billion dollar new German plant - sources,"U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a press conference for Friday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/lilly-plans-single-digit-billion-dollar-new-german-plant-sources-2023-11-15/,https://images.financialmodelingprep.com/news/lilly-plans-singledigit-billion-dollar-new-german-plant-sources-20231115.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-15 18:00:00,2023-11-15T18:00:00-05:00,2023-11-15,Why Eli Lilly Stock Flopped While the Market Popped Today,A media report stated that the pharmaceutical giant intends to build a new factory in Germany. It will apparently fund the project entirely on its own.,fool.com,https://www.fool.com/investing/2023/11/15/why-eli-lilly-stock-flopped-while-the-market-poppe/,https://images.financialmodelingprep.com/news/why-eli-lilly-stock-flopped-while-the-market-popped-20231115.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-16 05:17:37,2023-11-16T05:17:37-05:00,2023-11-16,Eli Lilly plans to invest 2 bln euros in new German plant -source,"U.S. pharma company Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-invest-2-bln-euros-new-german-plant-source-2023-11-16/,https://images.financialmodelingprep.com/news/eli-lilly-plans-to-invest-2-bln-euros-in-20231116.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-16 06:19:09,2023-11-16T06:19:09-05:00,2023-11-16,Eli Lilly: Perfectly Priced Healthcare Giant,"Eli Lily has the highest market capitalization of any Healthcare company, but its low revenue does not justify its lofty valuation at first glance. However, the company's average 5-year forward growth of 16.8% explains the market's pricing of its stock. With a steady pipeline of products with a high focus on Diabetes/Obesity drugs, the company's outlook certainly justifies its position as the highest-valued healthcare stock.",seekingalpha.com,https://seekingalpha.com/article/4652291-eli-lilly-perfectly-priced-healthcare-giant,https://images.financialmodelingprep.com/news/eli-lilly-perfectly-priced-healthcare-giant-20231116.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-16 06:26:17,2023-11-16T06:26:17-05:00,2023-11-16,Eli Lilly plans new 2 billion euro German plant -source,"U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-plans-new-2-bln-euro-german-plant-source-2023-11-16/,https://images.financialmodelingprep.com/news/eli-lilly-plans-new-2-billion-euro-german-plant-20231116.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-16 08:30:08,2023-11-16T08:30:08-05:00,2023-11-16,This Option Trade On Eli Lilly Stock Could Return 27% By Mid-January,This iron condor trade on Lilly stock has the potential to return 27% if the stock price stays between about 510 and 680.,investors.com,https://www.investors.com/research/options/eli-lilly-stock-option-trade-benefits-from-decay/,https://images.financialmodelingprep.com/news/this-option-trade-on-eli-lilly-stock-could-return-20231116.jpg
LLY,2023-11-02,2023-10-19,2023-11-16,LLY,,2023-11-16 09:00:00,2023-11-16T09:00:00-05:00,2023-11-16,Better Growth Stock: Novo Nordisk vs. Eli Lilly,Novo Nordisk and Eli Lilly are both leaders in the diabetes care market. Both have been recording excellent financial results for most of the year.,fool.com,https://www.fool.com/investing/2023/11/16/better-growth-stock-novo-nordisk-vs-eli-lilly/,https://images.financialmodelingprep.com/news/better-growth-stock-novo-nordisk-vs-eli-lilly-20231116.jpg
